Cargando…

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer

Detalles Bibliográficos
Autores principales:	Evans, Jonathan P., Winiarski, Boleslaw K., Sutton, Paul A., Jones, Robert P., Ressel, Lorenzo, Duckworth, Carrie A., Pritchard, D. Mark, Lin, Zhi-Xiu, Fretwell, Vicky L., Tweedle, Elizabeth M., Costello, Eithne, Goldring, Christopher E., Copple, Ian M., Park, B. Kevin, Palmer, Daniel H., Kitteringham, Neil R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363008/ https://www.ncbi.nlm.nih.gov/pubmed/30774766 http://dx.doi.org/10.18632/oncotarget.26625

Ejemplares similares

The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
por: Evans, Jonathan P., et al.
Publicado: (2018)

Development of an orthotopic syngeneic murine model of colorectal cancer for use in translational research
por: Evans, Jonathan P, et al.
Publicado: (2019)

Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2
por: Olayanju, Adedamola, et al.
Publicado: (2015)

Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
por: Lister, Adam, et al.
Publicado: (2011)

Brusatol, an NRF2 inhibitor for future cancer therapeutic
por: Cai, Sabrina J., et al.
Publicado: (2019)

Brusatol
por: Hu, Shu-Zhi, et al.
Publicado: (2012)

Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney
por: Shelton, Luke M., et al.
Publicado: (2015)

Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway
por: Xiang, Yukai, et al.
Publicado: (2018)

Physical and Functional Interaction of Sequestosome 1 with Keap1 Regulates the Keap1-Nrf2 Cell Defense Pathway
por: Copple, Ian M., et al.
Publicado: (2010)

Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: Biochemical, pharmacological and toxicological implications
por: Walsh, Joanne, et al.
Publicado: (2014)

The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers
por: Tian, Ziyin, et al.
Publicado: (2022)

UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response
por: Wang, Mei, et al.
Publicado: (2018)

Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma
por: Lee, Jong Hyun, et al.
Publicado: (2019)

UHRF1 regulation of the Keap1–Nrf2 pathway in pancreatic cancer contributes to oncogenesis
por: Abu‐Alainin, Wafa, et al.
Publicado: (2015)

Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts
por: Chang, Qing, et al.
Publicado: (2010)

The toxic effects and possible mechanisms of Brusatol on mouse oocytes
por: Ma, Rujun, et al.
Publicado: (2017)

Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumor Effect in Breast Cancer by Targeting Nrf2 Signaling Pathway
por: Li, Jing, et al.
Publicado: (2023)

Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells
por: Chen, Hai-Ming, et al.
Publicado: (2018)

Brusatol: A potential anti-tumor quassinoid from Brucea javanica
por: Yu, Xiao-qi, et al.
Publicado: (2020)

Differential effect of covalent protein modification and glutathione depletion on the transcriptional response of Nrf2 and NF-κB()
por: Chia, Alvin J.L., et al.
Publicado: (2010)

Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas
por: Wu, Zerui, et al.
Publicado: (2021)

Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1
por: Dai, Zhang’an, et al.
Publicado: (2021)

Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo
por: Ge, Shushan, et al.
Publicado: (2020)

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
por: Yang, Yun, et al.
Publicado: (2020)

Larvicidal Activity of Brusatol Isolated from Brucea javanica (L) Merr on Culex quinquefasciatus
por: SUTININGSIH, Dwi, et al.
Publicado: (2019)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

Real-time in vivo imaging reveals localised Nrf2 stress responses associated with direct and metabolism-dependent drug toxicity
por: Forootan, Shiva S., et al.
Publicado: (2017)

Antitumour Antibiotics
por: Fox, B. W.
Publicado: (1979)

Brusatol Enhances the Radiosensitivity of A549 Cells by Promoting ROS Production and Enhancing DNA Damage
por: Sun, Xiaohui, et al.
Publicado: (2016)

Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies
por: Lu, Zheng, et al.
Publicado: (2017)

Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma
por: Lee, Jong Hyun, et al.
Publicado: (2020)

Antitumor Effect of Brusatol in Acute Lymphoblastic Leukemia Models Is Triggered by Reactive Oxygen Species Accumulation
por: Jorge, Joana, et al.
Publicado: (2022)

Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver
por: Kitteringham, Neil R., et al.
Publicado: (2010)

Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response
por: Li, Haiyan, et al.
Publicado: (2011)

Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids
por: Copple, Ian M., et al.
Publicado: (2014)

Redox-sensitive micelles composed of disulfide-linked Pluronic-linoleic acid for enhanced anticancer efficiency of brusatol
por: Zhang, Jinming, et al.
Publicado: (2018)

Brusatol Derivative–34 Attenuates Allergic Airway Inflammation Via Inhibition of the Spleen Tyrosine Kinase Pathway
por: Ding, Yasi, et al.
Publicado: (2021)

Brusatol Inhibits Proliferation and Metastasis of Colorectal Cancer by Targeting and Reversing the RhoA/ROCK1 Pathway
por: Lu, Rui-jin, et al.
Publicado: (2022)

Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
por: Rossin, Raffaella, et al.
Publicado: (2018)

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
por: Fu, Wenyan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3tma1ve7ljn1kndtvbtc3mugrm